Pancreatic Cancer Research

ResearcherNippon Medical SchoolActive in the last 2 years

Toshiyuki Ishiwata

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4180-0069; OpenAlex author ID A5027281595, A5108471226. Sources: OpenAlex.

Their work

Papers
36 (first author 3, last author 24)
Trials
0
Grants
0
Labs led
2
Collaborators
26
Papers, trials and grants by year

2011: 1 paper · 2012: 5 papers · 2013: 1 paper · 2014: 3 papers · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: 5 papers · 2019: 5 papers · 2020: 2 papers · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 4 papers

Papers 36

  1. Heterogeneous expression of the laminin-binding O-mannosyl glycan on α-dystroglycan in pancreatic cancer cell line MIA PaCa-2 and the correlation with cell pro… Co-author DOI 10.1016/j.bbagen.2026.130907↗
  2. Single-cell analysis of anchorage-independent growth ability in pancreatic ductal adenocarcinoma cell lines. Last author DOI 10.1186/s13104-026-07670-4↗
  3. Mucin expression in pancreatic ductal adenocarcinoma cell lines in 2D and 3D cultures: A proteomic and immunocytochemical analysis. Last author DOI 10.1371/journal.pone.0353991↗
  4. Proteomic and immunocytochemical analyses of squamous components in two- and three-dimensional-cultured pancreatic ductal adenocarcinoma cell lines. Last author DOI 10.3892/ol.2026.15540↗
  5. Transmission electron microscopic analysis of pancreatic ductal adenocarcinoma cell spheres formed in 3D cultures. Last author DOI 10.1007/s00795-025-00435-1↗
  6. Cytotoxic and senescence-inducing effects of BLU554 in pancreatic ductal adenocarcinoma: an in vitro study. Last author DOI 10.1186/s12885-025-15317-z↗
  7. Artificial intelligence-based analysis of time-lapse images of sphere formation and process of plate adhesion and spread of pancreatic cancer cells. Last author DOI 10.3389/fcell.2023.1290753↗
  8. Gp130-Mediated STAT3 Activation Contributes to the Aggressiveness of Pancreatic Cancer through H19 Long Non-Coding RNA Expression. Last author DOI 10.3390/cancers14092055↗
  9. Epithelial and Mesenchymal Features of Pancreatic Ductal Adenocarcinoma Cell Lines in Two- and Three-Dimensional Cultures. Last author DOI 10.3390/jpm12050746↗
  10. Polyvinyl alcohol increased growth, migration, invasion, and sphere size in the PK-8 pancreatic ductal adenocarcinoma cell line. Last author DOI 10.1016/j.heliyon.2021.e06182↗
  11. Morphofunctional analysis of human pancreatic cancer cell lines in 2- and 3-dimensional cultures. Last author DOI 10.1038/s41598-021-86028-1↗
  12. Characterization of the metastatic potential of the floating cell component of MIA PaCa-2, a human pancreatic cancer cell line. Last author DOI 10.1016/j.bbrc.2019.11.120↗
  13. FGFR4 Inhibitor BLU9931 Attenuates Pancreatic Cancer Cell Proliferation and Invasion While Inducing Senescence: Evidence for Senolytic Therapy Potential in Pan… Last author DOI 10.3390/cancers12102976↗
  14. Fetal bovine serum enlarges the size of human pancreatic cancer spheres accompanied by an increase in the expression of cancer stem cell markers. Last author DOI 10.1016/j.bbrc.2019.04.117↗
  15. Enhanced morphological and functional differences of pancreatic cancer with epithelial or mesenchymal characteristics in 3D culture. Last author DOI 10.1038/s41598-019-47416-w↗
  16. Ganglioside GM2, highly expressed in the MIA PaCa-2 pancreatic ductal adenocarcinoma cell line, is correlated with growth, invasion, and advanced stage. Last author DOI 10.1038/s41598-019-55867-4↗
  17. The stem cell-specific intermediate filament nestin missense variation p.A1199P is associated with pancreatic cancer. Co-author DOI 10.3892/ol.2019.10106↗
  18. Overexpression of carbohydrate sulfotransferase 15 in pancreatic cancer stroma is associated with worse prognosis. Co-author DOI 10.3892/ol.2019.10764↗
  19. Pancreatic cancer stem cells: features and detection methods. Co-author DOI 10.1007/s12253-018-0420-x↗
  20. Reduced expression of the H19 long non-coding RNA inhibits pancreatic cancer metastasis. Last author DOI 10.1038/s41374-018-0048-1↗
  21. Stemness and anti-cancer drug resistance in ATP-binding cassette subfamily G member 2 highly expressed pancreatic cancer is induced in 3D culture conditions. First author DOI 10.1111/cas.13533↗
  22. H19 long non-coding RNA contributes to sphere formation and invasion through regulation of CD24 and integrin expression in pancreatic cancer cells. Last author DOI 10.18632/oncotarget.26176↗
  23. Electron microscopic analysis of different cell types in human pancreatic cancer spheres. Co-author DOI 10.3892/ol.2017.7554↗
  24. Nestin phosphorylation at threonines 315 and 1299 correlates with proliferation and metastasis of human pancreatic cancer. First author DOI 10.1111/cas.13139↗
  25. Systemic Administration of Small Interfering RNA Targeting Human Nestin Inhibits Pancreatic Cancer Cell Proliferation and Metastasis. First author DOI 10.1097/mpa.0000000000000427↗
  26. Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion. Co-author DOI 10.3892/or.2016.4727↗
  27. Nestin delineates pancreatic cancer stem cells in metastatic foci of NOD/Shi-scid IL2Rγ(null) (NOG) mice. Last author DOI 10.1016/j.ajpath.2013.11.014↗
  28. Epithelial splicing regulatory protein 1 is a favorable prognostic factor in pancreatic cancer that attenuates pancreatic metastases. Last author DOI 10.1038/onc.2013.392↗
  29. Inhibition of fibroblast growth factor receptor 2 attenuates proliferation and invasion of pancreatic cancer. Last author DOI 10.1111/cas.12470↗
  30. Nestin regulates epithelial-mesenchymal transition marker expression in pancreatic ductal adenocarcinoma cell lines. Last author DOI 10.3892/mco.2012.1↗
  31. Nestin and other putative cancer stem cell markers in pancreatic cancer. Last author DOI 10.1007/s00795-012-0571-x↗
  32. Enhanced expression of fibroblast growth factor receptor 2 IIIc promotes human pancreatic cancer cell proliferation. Co-author DOI 10.1016/j.ajpath.2012.01.020↗
  33. Secreted 70kDa lumican stimulates growth and inhibits invasion of human pancreatic cancer. Co-author DOI 10.1016/j.canlet.2012.01.023↗
  34. Keratinocyte growth factor induces matrix metalloproteinase-9 expression and correlates with venous invasion in pancreatic cancer. Last author DOI 10.3892/ijo.2011.1280↗
  35. Nestin as a novel therapeutic target for pancreatic cancer via tumor angiogenesis. Co-author DOI 10.3892/ijo.2012.1333↗
  36. Nestin is a novel target for suppressing pancreatic cancer cell migration, invasion and metastasis. Last author DOI 10.4161/cbt.11.5.14673↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuuki Shichi · 12 shared papers, 2019–2026 · strength 2.68
  2. Tomio Arai · 15 shared papers, 2016–2026 · strength 2.10
  3. Masakazu Fujiwara · 7 shared papers, 2019–2026 · strength 1.61
  4. Fujiya Gomi · 11 shared papers, 2019–2025 · strength 1.60
  5. Norihiko Sasaki · 14 shared papers, 2018–2022 · strength 1.56
  6. Yoko Matsuda · 17 shared papers, 2011–2020 · strength 1.26
  7. Masashi Toyoda · 10 shared papers, 2018–2022 · strength 1.13
  8. Hisashi Yoshimura · 10 shared papers, 2014–2022 · strength 0.85
  9. Junko Aida · 6 shared papers, 2018–2019 · strength 0.49
  10. Rieko Imae · 1 shared paper, 2026 · strength 0.39
  11. Hiroshi Manya · 1 shared paper, 2026 · strength 0.39
  12. Zenya Naito · 8 shared papers, 2011–2016 · strength 0.36
  13. Fuuka Minami · 2 shared papers, 2021 · strength 0.28
  14. Murray Korc · 5 shared papers, 2011–2020 · strength 0.27
  15. Eiji Uchida · 5 shared papers, 2012–2016 · strength 0.24
  16. Akira Matsushita · 2 shared papers, 2016–2022 · strength 0.23
  17. Junji Ueda · 3 shared papers, 2012–2014 · strength 0.13
  18. Makoto Nishimura · 1 shared paper, 2019 · strength 0.11
  19. Kenichi Hirabayashi · 1 shared paper, 2019 · strength 0.09
  20. Naoya Nakamura · 1 shared paper, 2019 · strength 0.09
  21. Toshinari Minamoto · 1 shared paper, 2017 · strength 0.08
  22. Tetsushi Yamamoto · 2 shared papers, 2012 · strength 0.08
  23. Toshikazu Ushijima · 1 shared paper, 2016 · strength 0.07
  24. Hiroki Sumiyoshi · 1 shared paper, 2016 · strength 0.07
  25. Masahito Hagio · 1 shared paper, 2013 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.